Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avidity Biosciences (RNA) Total Non-Current Liabilities (2019 - 2020)

Historic Total Non-Current Liabilities for Avidity Biosciences (RNA) over the last 2 years, with Q3 2020 value amounting to $26.0 million.

  • Avidity Biosciences' Total Non-Current Liabilities changed N/A to $26.0 million in Q3 2020 from the same period last year, while for Sep 2020 it was $26.0 million, marking a year-over-year change of. This contributed to the annual value of $27.5 million for FY2019, which is N/A changed from last year.
  • Avidity Biosciences' Total Non-Current Liabilities amounted to $26.0 million in Q3 2020.
  • Avidity Biosciences' 5-year Total Non-Current Liabilities high stood at $27.5 million for Q4 2019, and its period low was $25.1 million during Q2 2020.